Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
United Laboratories International Holdings (STU:UNJ) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
United Laboratories International Holdings EBITDA Margin % Related Terms
United Laboratories International Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings EBITDA Margin % Chart
United Laboratories International Holdings Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Laboratories International Holdings EBITDA Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings (STU:UNJ) has a EBITDA Margin % of 8.70% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on United Laboratories International Holdings and its competitors. This is 61% below median its historical median of 22.37. Over the past decade, United Laboratories International Holdings' EBITDA Margin % has ranged from 13.38 to 28.94. According to the industry distribution chart, United Laboratories International Holdings ranks #214 out of 961 companies in the Drug Manufacturers industry, placing it in the top 22.3%.
Is United Laboratories International Holdings' EBITDA Margin % too high?
United Laboratories International Holdings' current EBITDA Margin % of 8.70% is 61% below median its 10-year median of 22.37. Over the past 10 years, this metric has ranged from a low of 13.38 to a high of 28.94. The Drug Manufacturers industry median EBITDA Margin % is 12.49. United Laboratories International Holdings' value of 8.70% is 30.3% below this industry median. Based on the distribution chart, United Laboratories International Holdings ranks #214 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, United Laboratories International Holdings has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does United Laboratories International Holdings' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, United Laboratories International Holdings ranks #214 out of 961 companies for EBITDA Margin %. This places United Laboratories International Holdings in the top 22% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.49. United Laboratories International Holdings' value of 8.70% is 30.3% below this benchmark. Historically, United Laboratories International Holdings' own EBITDA Margin % has ranged from 13.38 to 28.94 over the past decade. While the company's 10-year median is 22.37 vs. the industry median of 12.49, United Laboratories International Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Laboratories International Holdings's current EBITDA Margin % of 8.70% is 30.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on United Laboratories International Holdings and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Laboratories International Holdings's current EBITDA Margin % is 8.70%, which is 61% below median its own 10-year median of 22.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Laboratories International Holdings stock overvalued right now?
Based on GuruFocus' analysis, United Laboratories International Holdings (STU:UNJ) is currently considered Fairly Valued. The stock's GF Value™ is €0.93, compared to a current price of €1.00 — trading 7% above its estimated fair value. The current EBITDA Margin % is 8.70%, which is 61% below median its 10-year median of 22.37 and 30.3% below the Drug Manufacturers industry median of 12.49. United Laboratories International Holdings' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For United Laboratories International Holdings (STU:UNJ), the current EBITDA Margin % is 8.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Laboratories International Holdings (STU:UNJ) Overvalued in 2026?
Based on GuruFocus' analysis, United Laboratories International Holdings stock appears to be overvalued.
The current stock price of €1.00 is trading 7% above its estimated GF Value™ of €0.93.
GuruFocus considers United Laboratories International Holdings to be Fairly Valued.
Key valuation signals for STU:UNJ:
EBITDA Margin %: 8.70% (61% below median its 10-year median of 22.37)
GF Value™: €0.93 vs. price of €1.00 (7% above fair value)
Industry Position: 30.3% below the Drug Manufacturers median (#214 of 961)
No single metric tells the full story. See the STU:UNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Laboratories International Holdings Business Description
United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Finished products segment, followed by Bulk medicine. The majority of the company's sales are generated in China, followed by Europe, India and other countries.
65GF Score
Get the complete analysis for STU:UNJ
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:UNJ has been successfully added to your 
